Back to Journals » Clinical Ophthalmology » Volume 3

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension

Authors Teus M, Miglior S, Laganovska G, Volksone L, Romanowska-Dixon B, Gos R, Holló G

Published 13 November 2009 Volume 2009:3 Pages 629—636

DOI https://doi.org/10.2147/OPTH.S8011

Review by Single anonymous peer review

Peer reviewer comments 3


Miguel A Teus1, Stefano Miglior2, Guna Laganovska3, Lasma Volksone4, Bozena Romanowska-Dixon5, Roman Gos6, Gábor Holló7, for the C-05-25 Study Group8

1Hospital Príncipe de Astúrias, Universidad de Alcalá, Madrid, Spain; 2Clinica Oculistica, Policlinico di Monza Università di Milano Bicocca, Monza (MI), Italy; 3Department of Ophthalmology, Stradina Clinical University Hospital, Riga, Latvia; 4Glaucoma Service, Clinical Hospital Gailezera, Riga, Latvia; 5Szpital Uniwersytecki w Krakowie, Kraków, Poland; 6Contact-Med, Sp. z o.o., Łódź, Poland; 7Semmelweis University, Department of Ophthalmology, Budapest, Hungary; 8The C-05-25 Study Group: Members are listed under Acknowledgments

Purpose: To compare the intraocular pressure- (IOP-) lowering efficacy of fixed combinations travoprost 0.004%/timolol 0.5% and dorzolamide 2%/timolol 0.5% in patients with ocular hypertension or open-angle glaucoma.

Methods: In this prospective, multicenter, double-masked, randomized clinical trial, 319 qualifying patients received either travoprost/timolol once daily in the morning (n = 157) or dorzolamide/timolol twice daily (n = 162). IOP was assessed morning and evening at 2 and 6 weeks. The primary outcome measure was mean diurnal IOP.

Results: Baseline mean IOP values were similar between groups. Mean pooled diurnal IOP was significantly lower in the travoprost/timolol group (16.5 mmHg ± 0.23) than in the dorzolamide/timolol group (17.3 mmHg ± 0.23; P = 0.011). Mean IOP was significantly lower in the travoprost/timolol group compared to the dorzolamide/timolol group at the 9 AM time point both at Week 2 (P = 0.006) and Week 6 (P = 0.002). The travoprost/timolol combination produced mean IOP reductions from baseline of 35.3% to 38.5%, while the dorzolamide/timolol combination produced mean IOP reductions from baseline of 32.5% to 34.5%. Conclusions: The fixed combination travoprost 0.004%/timolol 0.5% dosed once daily in the morning demonstrated superior mean diurnal IOP-lowering efficacy compared to dorzolamide 2%/timolol 0.5% dosed twice daily in patients with ocular hypertension or open-angle glaucoma.

Keywords: dorzolamide, fixed combination, glaucoma, IOP-lowering therapy, timolol, travoprost

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]